77 related articles for article (PubMed ID: 24295412)
1. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M; Khot A
Future Oncol; 2013 Dec; 9(12):1819-27. PubMed ID: 24295412
[TBL] [Abstract][Full Text] [Related]
2. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma.
Shih BB; Ma C; Cortes JR; Reglero C; Miller H; Quinn SA; Albero R; Laurent AP; Mackey A; Ferrando AA; Geskin L; Palomero T
J Invest Dermatol; 2024 Jul; 144(7):1579-1589.e8. PubMed ID: 38219917
[TBL] [Abstract][Full Text] [Related]
4. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
6. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
Biomark Res; 2014; 2():16. PubMed ID: 25279222
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
10. Afatinib in the treatment of breast cancer.
Hurvitz SA; Shatsky R; Harbeck N
Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):17-8. PubMed ID: 24852793
[No Abstract] [Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity to romidepsin.
Kakar R; Rommel J; McKinley-Grant L; Shenoy AG; DeSimone JA
J Am Acad Dermatol; 2014 Jan; 70(1):e21-2. PubMed ID: 24355282
[No Abstract] [Full Text] [Related]
14. Pharmacology of irinotecan.
Kuhn JG
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):39-42. PubMed ID: 9726089
[TBL] [Abstract][Full Text] [Related]
15. Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors.
Hearn KN; Ashton TD; Acharya R; Feng Z; Gueven N; Pfeffer FM
Cells; 2021 Jun; 10(6):. PubMed ID: 34203745
[TBL] [Abstract][Full Text] [Related]
16. An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation.
Hesping E; Skinner-Adams TS; Fisher GM; Kurz T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():249-256. PubMed ID: 33279862
[TBL] [Abstract][Full Text] [Related]
17. Natural Products Impacting DNA Methyltransferases and Histone Deacetylases.
Akone SH; Ntie-Kang F; Stuhldreier F; Ewonkem MB; Noah AM; Mouelle SEM; Müller R
Front Pharmacol; 2020; 11():992. PubMed ID: 32903500
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors.
Zhang JH; Mottamal M; Jin HS; Guo S; Gu Y; Wang G; Zhao LM
Future Med Chem; 2019 Nov; 11(21):2765-2778. PubMed ID: 31702394
[No Abstract] [Full Text] [Related]
19. The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells.
Clarke K; Young C; Liberante F; McMullin MF; Thompson A; Mills K
Oncotarget; 2019 May; 10(37):3462-3471. PubMed ID: 31191819
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.
Wobser M; Weber A; Glunz A; Tauch S; Seitz K; Butelmann T; Hesbacher S; Goebeler M; Bartz R; Kohlhof H; Schrama D; Houben R
J Hematol Oncol; 2019 Mar; 12(1):30. PubMed ID: 30885250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
